Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
8.00
-0.03 (-0.37%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Kalaris Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Selling, General & Admin | 6.69 | 1.76 | 2.24 |
| Research & Development | 45.04 | 11.71 | 11.76 |
| Operating Expenses | 51.73 | 13.46 | 14.01 |
| Operating Income | -51.73 | -13.46 | -14.01 |
| Interest Expense | -40.72 | -1.58 | -1.03 |
| Other Non Operating Income (Expenses) | 23.28 | 0.34 | 0.75 |
| EBT Excluding Unusual Items | -69.17 | -14.7 | -14.29 |
| Other Unusual Items | - | - | -1.2 |
| Pretax Income | -69.17 | -14.7 | -15.49 |
| Net Income | -69.17 | -14.7 | -15.49 |
| Net Income to Common | -69.17 | -14.7 | -15.49 |
| Shares Outstanding (Basic) | 7 | 6 | 4 |
| Shares Outstanding (Diluted) | 7 | 6 | 4 |
| Shares Change (YoY) | 9.18% | 36.56% | - |
| EPS (Basic) | -10.44 | -2.42 | -3.48 |
| EPS (Diluted) | -10.44 | -2.42 | -3.48 |
| EBIT | -51.73 | -13.46 | -14.01 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.